News

Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.

A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.

The founder of PSC Partners Seeking a Cure discusses how screening and treatment for the rare disease has evolved since her diagnosis 20 years ago.

A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

Patients with systemic lupus erythematosus exhibited comparable or higher incidence rates of infection in the placebo cohort compared with belimumab.

Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.

This new research presented at ACR Convergence 2023 led to several notable findings for patients with rheumatoid arthritis.

At the end of year 2, 80% of patients on faricimab reached > q12 week dosing, and 63% achieved q16 dosing.

Marc Bonaca, MD, discusses an AHA 2023 study he led examining trends in discordance between LVEF and ICD-10 codes used in heart failure hospitalizations.

Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.

Severity-dependent anemia and low hemoglobin levels were significant risk factors for stroke/transient ischemic attack and bleeding in patients with atrial fibrillation treated with warfarin.

Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.

A study followed a neonatal cohort with sickle cell disease for up to 20 years. The study demonstrated how hydroxyurea lowers the risk of high mortality.

This new data may help health policymakers to better strategize their approaches to management of childrens’ nutritional anemias.

60.2% of infant living-related liver transplant recipients developed AKI within 7 days of surgery and experienced more frequent serious complications, longer hospital stays, and a greater duration of postoperative mechanical ventilation compared to those who did not develop AKI.

The FDA announced it has approved Adzynma as prophylactic or on-demand enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Research demonstrates eltrombopag is a safe and effective treatment option for patients with refractory or relapsed severe aplastic anemia, with 70% of patients achieving hematologic response at week 26.

Investigators studied factors that could be associated with anemia in children < 5 years old, such as gender, age in years, type of birth (single or multiple), birth order, preceding birth interval in months (<18 months, 18+ months, or 1st born), and fever or no fever in the past 2 weeks (with malaria and without). Other factors related to mother or caregiver characteristics and household characteristics.

This new data showed that spreading awareness about pneumococcal infection and prophylaxis could help to improve health outcomes and reduce mortality related to infections in those with SCD.

Decreased blood serum cholesterol levels were associated with an increased risk of plasma cell neoplasm, although there was no causal association with multiple myeloma.

On November 7, 2023, Recor Medical announced the FDA approval of their Paradise Ultrasound Renal Denervation system for the treatment of hypertension.

Presented at AAO 2023, a study analyzed which race was associated more with having a glaucoma-associated diagnosis, as well as races’ knowledge, attitude, and beliefs about eye care.

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.

Eligibility criteria prevents more Black individuals than White individuals from participating in clinical trials for diabetic macular edema.

In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.

At the 7-month mark, multivariate analysis revealed patients with psoriasis aged ≥65 years reported a significantly better response to tildrakizumab.

This new research looked at a nationwide birth cohort of mother–child pairs in Japan, allowing for a wide array of data on this less well-studied topic.

How does rheumatoid arthritis affect the risk of osteoporosis-related fracture, and is its impact the same for both men and women? Test your knowledge with this quiz.

Announced on November 8, 2023, the approval of tirzepatide(Zepbound) was awarded to Eli Lilly and Company and represents the first chronic weight management approval for a dual GLP-1/GIP receptor agonist.